Literature DB >> 17381470

Liver disease as risk factor for cystic fibrosis-related diabetes development.

L Minicucci1, R Lorini, A Giannattasio, C Colombo, L Iapichino, M F Reali, R Padoan, M G Calevo, R Casciaro, A De Alessandri, R Haupt.   

Abstract

AIM: To evaluate clinical and genetic factors, besides pancreatic insufficiency, associated with increased risk of cystic fibrosis-related diabetes.
METHODS: Case-control (1:1) study on 138 cystic fibrosis patients. Data were collected on gender, age at diagnosis, reason for cystic fibrosis diagnosis, family history of type 1 or 2 diabetes mellitus, pre-existing severe liver disease, and class of cystic fibrosis transmembrane regulation mutation. Moreover, information was obtained on lung involvement and degree of exocrine pancreatic insufficiency evaluated 1 year before the diagnosis of cystic fibrosis-related diabetes in patients and age-matched controls.
RESULTS: Compared to controls, patients with cystic fibrosis-related diabetes had a higher probability of having already been diagnosed with liver disease (16.7% versus 1.7%, OR = 11.6, 95% CI 1.43-93.0). Moreover, in the year before diabetes onset, cases had slightly worse pulmonary function compared to controls (FEV1 = 58.4 +/- 27% predicted versus 67.4 +/- 21% predicted; p = 0.05). No significant effects related to the other factors considered were found.
CONCLUSION: Severe liver disease was found to significantly increase the risk of developing cystic fibrosis-related diabetes. Patients with liver disease should be scheduled for earlier diabetes screening in order to identify and possibly treat glucose intolerance.

Entities:  

Mesh:

Year:  2007        PMID: 17381470     DOI: 10.1111/j.1651-2227.2007.00250.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  14 in total

1.  Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets.

Authors:  Alicia K Olivier; Yaling Yi; Xingshen Sun; Hongshu Sui; Bo Liang; Shanming Hu; Weiliang Xie; John T Fisher; Nicholas W Keiser; Diana Lei; Weihong Zhou; Ziying Yan; Guiying Li; Turan I A Evans; David K Meyerholz; Kai Wang; Zoe A Stewart; Andrew W Norris; John F Engelhardt
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

Review 2.  Endocrine Disorders in Cystic Fibrosis.

Authors:  Scott M Blackman; Vin Tangpricha
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

3.  Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis.

Authors:  Scott M Blackman; Stephanie Hsu; Lori L Vanscoy; J Michael Collaco; Sarah E Ritter; Kathleen Naughton; Garry R Cutting
Journal:  J Clin Endocrinol Metab       Date:  2009-01-06       Impact factor: 5.958

Review 4.  Cirrhosis and other liver disease in cystic fibrosis.

Authors:  Thomas Flass; Michael R Narkewicz
Journal:  J Cyst Fibros       Date:  2012-12-20       Impact factor: 5.482

Review 5.  Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation.

Authors:  Hubert P J van der Doef; Freddy T M Kokke; Cornelis K van der Ent; Roderick H J Houwen
Journal:  Curr Gastroenterol Rep       Date:  2011-06

6.  Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients.

Authors:  Pierre-Yves Boëlle; Dominique Debray; Loic Guillot; Annick Clement; Harriet Corvol
Journal:  Hepatology       Date:  2018-12-28       Impact factor: 17.425

Review 7.  Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors.

Authors:  Fernanda Iafusco; Giovanna Maione; Francesco Maria Rosanio; Enza Mozzillo; Adriana Franzese; Nadia Tinto
Journal:  Diagnostics (Basel)       Date:  2021-03-22

8.  Cystic fibrosis related liver disease and endocrine considerations.

Authors:  Jordan S Sherwood; Jagdeesh Ullal; Katherine Kutney; Kara S Hughan
Journal:  J Clin Transl Endocrinol       Date:  2021-12-13

9.  Genetic modifiers of cystic fibrosis-related diabetes.

Authors:  Scott M Blackman; Clayton W Commander; Christopher Watson; Kristin M Arcara; Lisa J Strug; Jaclyn R Stonebraker; Fred A Wright; Johanna M Rommens; Lei Sun; Rhonda G Pace; Sarah A Norris; Peter R Durie; Mitchell L Drumm; Michael R Knowles; Garry R Cutting
Journal:  Diabetes       Date:  2013-05-13       Impact factor: 9.461

10.  Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.

Authors:  Katherine Kutney; Shannon B Donnola; Chris A Flask; Rose Gubitosi-Klug; MaryAnn O'Riordan; Kimberly McBennett; Thomas J Sferra; Beth Kaminski
Journal:  World J Hepatol       Date:  2019-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.